Evaxion A (EVAX) Income from Continuing Operations (2020 - 2026)
Evaxion A's (EVAX) quarterly Income from Continuing Operations came in at 4061000.0 in Q1 2026, down 106.77% YoY from 59968451.13 in Q1 2025, and up 36.83% on a QoQ basis from 6429000.0 in Q4 2025.
Evaxion A (EVAX) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Evaxion A (EVAX) has 7 years of Income from Continuing Operations data on file, last reported at 4061000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 106.77% year-over-year to 4061000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 11624000.0 (up 20.75% YoY) and the FY2025 annual result came in at 9523000.0, up 21.58% from the prior year.
- Income from Continuing Operations grew to 4061000.0 in Q1 2026, from 6429000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 4087000.0 in Q3 2025 to a low of 7218000.0 in Q4 2022.
- A 5-year average of 3833823.53 and a median of 4877000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations plunged 680.8% — and 2025, when it surged 292.15%.
- Tracing EVAX's Income from Continuing Operations over 5 years: stood at 7218000.0 in 2022, then soared by 32.43% to 4877000.0 in 2023, then climbed by 14.31% to 4179000.0 in 2024, then tumbled by 53.84% to 6429000.0 in 2025, then surged by 36.83% to 4061000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 4061000.0 (Q1 2026), 6429000.0 (Q4 2025), and 4087000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Evaxion A | 27.61 Mn | 27.61 Mn | - | -4.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.06 Mn |
| Dec 31, 2025 | -6.43 Mn |
| Sep 30, 2025 | 4.09 Mn |
| Jun 30, 2025 | -5.22 Mn |
| Mar 31, 2025 | -1.96 Mn |
| Dec 31, 2024 | -4.18 Mn |
| Sep 30, 2024 | -2.13 Mn |
| Jun 30, 2024 | -6.40 Mn |
| Mar 31, 2024 | 758,000.00 |
| Dec 31, 2023 | -4.88 Mn |
| Sep 30, 2023 | -6.07 Mn |
| Jun 30, 2023 | -6.13 Mn |
| Mar 31, 2023 | -6.63 Mn |
| Dec 31, 2022 | -7.22 Mn |
| Sep 30, 2022 | -6.09 Mn |
| Jun 30, 2022 | -1.78 Mn |
| Mar 31, 2022 | -849,000.00 |
| Dec 31, 2021 | -5.72 Mn |
| Sep 30, 2021 | -19.16 Mn |
| Jun 30, 2021 | -653,000.00 |